Cargando…

Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma

BACKGROUND: Rhabdomyosarcoma (RMS), which can be classified as embryonal RMS (ERMS) and alveolar RMS (ARMS), represents the most frequent soft tissue sarcoma in the pediatric population; the latter shows greater aggressiveness and metastatic potential with respect to the former. Epigenetic alteratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Tombolan, L., Poli, E., Martini, P., Zin, A., Millino, C., Pacchioni, B., Celegato, B., Bisogno, G., Romualdi, C., Rosolen, A., Lanfranchi, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109816/
https://www.ncbi.nlm.nih.gov/pubmed/27842508
http://dx.doi.org/10.1186/s12885-016-2936-3
_version_ 1782467614657740800
author Tombolan, L.
Poli, E.
Martini, P.
Zin, A.
Millino, C.
Pacchioni, B.
Celegato, B.
Bisogno, G.
Romualdi, C.
Rosolen, A.
Lanfranchi, G.
author_facet Tombolan, L.
Poli, E.
Martini, P.
Zin, A.
Millino, C.
Pacchioni, B.
Celegato, B.
Bisogno, G.
Romualdi, C.
Rosolen, A.
Lanfranchi, G.
author_sort Tombolan, L.
collection PubMed
description BACKGROUND: Rhabdomyosarcoma (RMS), which can be classified as embryonal RMS (ERMS) and alveolar RMS (ARMS), represents the most frequent soft tissue sarcoma in the pediatric population; the latter shows greater aggressiveness and metastatic potential with respect to the former. Epigenetic alterations in cancer include DNA methylation changes and histone modifications that influence overall gene expression patterns. Different tumor subtypes are characterized by distinct methylation signatures that could facilitate early disease detection and greater prognostic accuracy. METHODS: A genome-wide approach was used to examine methylation patterns associated with different prognoses, and DNA methylome analysis was carried out using the Agilent Human DNA Methylation platform. The results were validated using bisulfite sequencing and 5-aza-2′deoxycytidine treatment in RMS cell lines. Some in vitro functional studies were also performed to explore the involvement of a target gene in RMS tumor cells. RESULTS: In accordance with the Intergroup Rhabdomyosarcoma Study (IRS) grouping, study results showed that distinct methylation patterns distinguish RMS subgroups and that a cluster of protocadherin genes are hypermethylated in metastatic RMS. Among these, PCDHA4, whose expression was decreased by DNA methylation, emerged as a down-regulated gene in the metastatic samples. As PCDHA4-silenced cells have a significantly higher cell proliferation rate paralleled by higher cell invasiveness, PCDHA4 seems to behave as a tumor suppressor in metastatic RMS. CONCLUSION: Study results demonstrated that DNA methylation patterns distinguish between metastatic and non-metastatic RMS and suggest that epigenetic regulation of specific genes could represent a novel therapeutic target that could enhance the efficiency of RMS treatments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2936-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5109816
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51098162016-11-21 Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma Tombolan, L. Poli, E. Martini, P. Zin, A. Millino, C. Pacchioni, B. Celegato, B. Bisogno, G. Romualdi, C. Rosolen, A. Lanfranchi, G. BMC Cancer Research Article BACKGROUND: Rhabdomyosarcoma (RMS), which can be classified as embryonal RMS (ERMS) and alveolar RMS (ARMS), represents the most frequent soft tissue sarcoma in the pediatric population; the latter shows greater aggressiveness and metastatic potential with respect to the former. Epigenetic alterations in cancer include DNA methylation changes and histone modifications that influence overall gene expression patterns. Different tumor subtypes are characterized by distinct methylation signatures that could facilitate early disease detection and greater prognostic accuracy. METHODS: A genome-wide approach was used to examine methylation patterns associated with different prognoses, and DNA methylome analysis was carried out using the Agilent Human DNA Methylation platform. The results were validated using bisulfite sequencing and 5-aza-2′deoxycytidine treatment in RMS cell lines. Some in vitro functional studies were also performed to explore the involvement of a target gene in RMS tumor cells. RESULTS: In accordance with the Intergroup Rhabdomyosarcoma Study (IRS) grouping, study results showed that distinct methylation patterns distinguish RMS subgroups and that a cluster of protocadherin genes are hypermethylated in metastatic RMS. Among these, PCDHA4, whose expression was decreased by DNA methylation, emerged as a down-regulated gene in the metastatic samples. As PCDHA4-silenced cells have a significantly higher cell proliferation rate paralleled by higher cell invasiveness, PCDHA4 seems to behave as a tumor suppressor in metastatic RMS. CONCLUSION: Study results demonstrated that DNA methylation patterns distinguish between metastatic and non-metastatic RMS and suggest that epigenetic regulation of specific genes could represent a novel therapeutic target that could enhance the efficiency of RMS treatments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2936-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-14 /pmc/articles/PMC5109816/ /pubmed/27842508 http://dx.doi.org/10.1186/s12885-016-2936-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tombolan, L.
Poli, E.
Martini, P.
Zin, A.
Millino, C.
Pacchioni, B.
Celegato, B.
Bisogno, G.
Romualdi, C.
Rosolen, A.
Lanfranchi, G.
Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma
title Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma
title_full Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma
title_fullStr Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma
title_full_unstemmed Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma
title_short Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma
title_sort global dna methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109816/
https://www.ncbi.nlm.nih.gov/pubmed/27842508
http://dx.doi.org/10.1186/s12885-016-2936-3
work_keys_str_mv AT tombolanl globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma
AT polie globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma
AT martinip globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma
AT zina globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma
AT millinoc globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma
AT pacchionib globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma
AT celegatob globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma
AT bisognog globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma
AT romualdic globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma
AT rosolena globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma
AT lanfranchig globaldnamethylationprofilinguncoversdistinctmethylationpatternsofprotocadherinalpha4inmetastaticandnonmetastaticrhabdomyosarcoma